A practical reference on LC-MS/MS: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-02-06. Anything still debated is marked as such rather than presented as settled.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Unapproved in the US, EU and Australia | Sale and import restricted; no licensed product |
| Typical test matrices | Urine, serum, seized powder | Urinary detection window is short |
| Primary identification method | LC-MS/MS against a reference standard | High-resolution mass used for confirmation |
| Data sources in the literature | Small trials, case reports, pharmacovigilance | No registrational trial dataset exists |
| Common marketing names | Melanotan 2, MT-II, MT-2 | Label content may not match declared peptide |
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Participation in rehabilitation programs during the early to middle stage of the disease may be beneficial as it translates into long-term maintenance of motor and functional performance. Rehabilitation during the late stage aims to compensate for motor and functional losses. For long-term independent management, the therapist may develop home exercise programs for appropriate people. Palliative care may also improve quality of life for people with HD by treating the symptoms and psychological stress of having a progressive degenerative disease.
the Extra-Terrestrial, Charles Nelson Reilly, characters from My Three Sons, and Kermit the Frog and Miss Piggy—in rapid succession. After completing his set, though getting the OK gesture from Carson, the impressionist comic was notably not waved over by the host to join him on the couch—a usual indication that while sufficiently pleased, the powerful host was probably not ecstatic about the performance. The end of 1983 saw Carrey go back home to Toronto once more for a publicized New Year's Eve performance at the Royal York Hotel's Imperial Room. Originally scheduled to start airing in January 1984, The Duck Factory sitcom debuted in April, airing Thursdays at 9:30pm between Cheers and Hill Street Blues. The same month, Carrey took a job hosting the 1984 U-Know Awards ceremony held in Toronto at the Royal York Hotel's Ballroom. By the time he made his debut appearance on NBC's Late Night with David Letterman in late July 1984, the network had already canceled The Duck Factory; Carrey went back to touring with his impressionist act, including often opening for Rodney Dangerfield. After being noticed doing stand-up by producer Samuel Goldwyn Jr. and contacted to audition for a teen horror sex comedy being developed by The Samuel Goldwyn Company, Carrey landed a starring role in Once Bitten shot in early 1985. Carrey would continue getting film roles; throughout late summer and early fall 1985, he shot a supporting part in Francis Ford Coppola's Peggy Sue Got Married which went into a long post-production process.
Bachem Holding AG is a Swiss biotechnology company specializing in the development and manufacture of peptides and complex organic molecules for use as active pharmaceutical ingredients (APIs). The company focuses on peptide-based therapeutics, including large-scale commercial production and process development for pharmaceutical applications. It was founded in 1971 and is a subsidiary of Ingro Finanz AG. The head office is in Bubendorf in the canton of Basel-Landschaft. Bachem operates production facilities in Vionnaz (Switzerland), Vista and Torrance (United States), and St Helens (United Kingdom), as well as a sales and distribution site in Tokyo. Bachem is one of the largest manufacturers of peptide-based APIs globally, supplying pharmaceutical and biotechnology companies with products used in both clinical development and commercial therapies. In recent years, the company has expanded its manufacturing capacity, including new large-scale production facilities in Switzerland and the United States. At the end of 2025, the company employed 2,511 people, reported revenue of CHF 695.1 million, and net income of CHF 148.8 million.
Sources: en.wikipedia.org
== Gene expression == During hair growth, as follicle bulb cells swiftly transform into cortical or cuticle hair keratinocytes, approximately 50-100 keratin genes become activated at the transcriptional level. However, this intricate process can be simplified into a few highly preserved gene families. In cortical keratinocytes, distinct patterns of keratin gene expression are evident, indicating the presence of different hierarchical transcription processes among various cell types. Examination of keratin gene promoter regions reveals conserved sequence motifs that might govern these cell-specific traits. Moreover, through the isolation of related sheep and human cuticle keratin genes, conserved DNA motifs and expression patterns during cuticle cell differentiation have been discovered. Further, the expression of sheep wool follicle IF and high-sulfur keratin genes in transgenic mice suggests that the regulatory DNA elements and proteins associated with hair keratin genes maintain functional conservation across mammalian species.
=== Breast cancer === Hormone antagonists are used widely in anticancer treatments, such as the drug tamoxifen, an anti-estrogen that binds to estrogen receptors to slow the growth of some estrogen receptor-positive breast cancers. Aromatase inhibitors (AIs) are also prescribed as a breast cancer treatment, especially after mastectomies. AIs work by blocking the action of the aromatase enzyme, which converts androgens, like testosterone, into estrogen. Aromatase inhibitors can be used in conjunction with estrogen receptor inhibitors to treat estrogen receptor-positive breast cancers in women who have gone through menopause already.
== History == Until the 1880s, the standard practice for treating a gunshot wound called for physicians to insert their unsterilized fingers into the wound to probe and locate the path of the bullet. Standard surgical theory such as opening abdominal cavities to repair gunshot wounds, germ theory, and Joseph Lister's technique for antiseptic surgery using diluted carbolic acid, had not yet been accepted as standard practice. For example, sixteen doctors attended to President James A. Garfield after he was shot in 1881, and most probed the wound with their fingers or dirty instruments. Historians agree that massive infection was a significant factor in Garfield's death. At almost the same time, in Tombstone, Arizona Territory, on 13 July 1881, George E. Goodfellow performed the first laparotomy to treat an abdominal gunshot wound. Goodfellow pioneered the use of sterile techniques in treating gunshot wounds, washing the person's wound and his hands with lye soap or whisky, and his patient, unlike the President, recovered. He became America's leading authority on gunshot wounds and is credited as the United States' first civilian trauma surgeon. Mid-nineteenth-century handguns such as the Colt revolvers used during the American Civil War had muzzle velocities of just 230 m/s and their powder and ball predecessors had velocities of 167 m/s or less. Unlike today's high-velocity bullets, nineteenth-century balls produced almost little or no cavitation and, being slower moving, they were liable to lodge in unusual locations at odds with their trajectory.
Before drying to make copra, raw coconut meat is 47% water, 33% fat, 15% carbohydrates, and 3% protein (table). In a reference amount of 100 grams (3.5 oz), raw coconut flesh supplies 354 calories of food energy, and is a rich source (20% or more of the Daily Value, DV) of manganese (65% DV), with various other dietary minerals in moderate amounts (10–18% DV; table). It is a poor source of vitamins. Raw coconut meat has a high content of saturated fatty acids (89% of total fats), with lauric acid as the main saturated fat (15% of total; USDA source in table).
Sources: en.wikipedia.org
An expanded genetic code is an artificially modified genetic code in which one or more specific codons have been re-allocated to encode an amino acid that is not among the 22 common naturally-encoded proteinogenic amino acids. The key prerequisites to expand the genetic code are:
Task Force 1–41 Infantry was the first coalition force to breach the Saudi Arabian border on 15 February 1991 and conduct ground combat operations in Iraq engaging in direct and indirect fire fights with the enemy on 17 February 1991. Prior to this action the Task Force's primary fire support battalion, 4th Battalion of the 3rd Field Artillery Regiment, participated in a massive artillery preparation. Around 300 guns from multiple countries participated in the artillery barrage. Over 14,000 rounds were fired during these missions. M270 Multiple Launch Rocket Systems contributed an additional 4,900 rockets fired at Iraqi targets. Iraq lost close to 22 artillery battalions during the initial stages of this barrage, including the destruction of approximately 396 Iraqi artillery pieces. By the end of these raids Iraqi artillery assets had all but ceased to exist. One Iraqi unit that was totally destroyed during the preparation was the Iraqi 48th Infantry Division Artillery Group. The group's commander stated his unit lost 83 of its 100 guns to the artillery preparation. The artillery bombardment was supplemented by Boeing B-52 Stratofortress bombing raids and Lockheed AC-130 attacks. AH-64 Apache attack helicopters from the 1st Infantry Division and B-52 bombers attacked the Iraqi 110th Infantry Brigade. Under enemy fire, the 1st and 9th Engineer Battalions marked and proofed assault lanes to secure a foothold in enemy territory and pass the 1st Infantry Division and the 1st Armoured Division forward.
=== csARDs === Conventional synthetic antirheumatic drugs (csARDs) are a class of disease-modifying medications. Unlike biologics or targeted synthetic drugs, which act on specific pathways in the immune system, csARDs have a broader effect on the immune system and are often considered traditional or conventional treatments. The most common drugs in this class are methotrexate and sulfasalazine. These medications are only used when others fail, or when certain specific conditions are met, and are often discontinued if a patient's symptoms become manageable with just a TNFi or other medication. Conventional DMARDs such as leflunomide are also considered to be part of this class. Concerns exist about a possible lack of efficacy of some drugs in this class.
== DTA == An alternative technique, which shares much in common with DSC, is differential thermal analysis (DTA). In this technique it is the heat flow to the sample and reference that remains the same rather than the temperature. When the sample and reference are heated identically, phase changes and other thermal processes cause a difference in temperature between the sample and reference. Both DSC and DTA provide similar information. DSC measures the energy required to keep both the reference and the sample at the same temperature whereas DTA measures the difference in temperature between the sample and the reference when the same amount of energy has been introduced into both.
Harkin responded by elevating OAM into an independent NIH "center", just short of being its own "institute", and renamed it the National Center for Complementary and Alternative Medicine (NCCAM). NCCAM had a mandate to promote a more rigorous and scientific approach to the study of alternative medicine, research training and career development, outreach, and "integration". Stephen Strauss was the director of NCCAM from 1999 to 2006. He tried to bring more scientific rigor to the organization. In 1999 the NCCAM budget was increased from $20 million to $50 million. The United States Congress approved the appropriations without dissent. In 2000, the budget was increased to about $68 million, in 2001 to $90 million, in 2002 to $104 million, and in 2003, to $113 million.
Sources: en.wikipedia.org
Regulatory treatment varies by country. In the United States, the European Union and Australia it is an unapproved drug and its sale is restricted, while some other jurisdictions list it as prescription-only or controlled. The applicable rules depend on the country of import.
Reversed-phase LC-MS/MS is the usual approach for both identification and quantitation. High-resolution mass spectrometry and peptide mapping serve as confirmatory methods. Immunoassays are rarely used alone because of cross-reactivity.
Published testing of seized and purchased samples frequently reports discrepancies between declared and measured peptide content. Counter-ion content and residual solvents add further variation. Independent analysis is the only way to confirm composition.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.